



Hungary

Recent and planned developments in pharmaceutical policies 2014

Policies related to high cost medicines

D E V E L O P M E N T S	Changes in pricing	Changes in reimbursement
	-	-
S P E C I A L T O P I C	Other changes	
	-	
High cost medicines		
<ul style="list-style-type: none"> • <u>Special pricing policies:</u> There are no specific pricing policies for high cost medicines. • <u>Special reimbursement/funding policies:</u> Item based reimbursement for high cost hospital products – disease registers. • <u>High cost medicines at the interface of out-patient and in-patient sectors:</u> Dual financing for all medicines in Hungary: In the out-patient sector: medicines included in the positive list are reimbursed by the social health insurance. In the in-patient sector: medicines are funded via the DRG system, except for 36 defined pharmaceuticals whose use is explicitly funded to the hospital. • <u>Key challenges and solutions:</u> planning the public procurement procedures uptake of biosimilars 		